Senti Bio Details Celadon Merger: CVRs Worth Up to $60M, Reverse Split, and Liquidation Warning
SNTI is trading near its 52-week low of $0.424 (11% above the low) on elevated volume (2.6× avg).
Summary
Senti Bio's proxy details a Celadon-led merger that spins off SENTI-202 for CVRs worth up to $60M, while the company warns liquidation would leave shareholders with nothing. The deal includes a reverse stock split and a $2.5M breakup fee.
Key Events · M&A and Partnerships · SNTI
-
Merger Spins Off Lead Asset for CVRs
A Celadon-controlled entity will acquire SENTI-202 through a merger of Midco. Public stockholders receive one CVR per share, entitling them to up to $60M in aggregate milestone payments: $10M upon BLA acceptance, $20M upon FDA approval, and $30M upon $200M cumulative net sales, all expiring in 7 years.
-
Liquidation Analysis Shows Zero Recovery
Management's liquidation analysis estimates a negative equity value of -$27.6M to -$23.3M, implying $0.00 per share for common stockholders. The company has a going-concern warning and cash runway only into Q3 2026.
-
Fairness Opinion Values CVRs at $0.07–$0.20/Share
Lincoln International's risk-adjusted present value of the CVRs is $0.07–$0.20 per share, reflecting low probability of success (18–42%) and long timelines (2030–2032). The maximum undiscounted payout is $1.05/share under current dilution.
-
Reverse Stock Split Proposed to Maintain Nasdaq Listing
Shareholders will vote on a reverse stock split at a ratio between 1-for-20 and 1-for-50 to boost the stock price above $1.00 and avoid delisting. The stock closed at $0.47 on July 21, 2026.
Analysis · SNTI · Life Sciences
Shareholders are being asked to approve a merger that spins off Senti Biosciences' lead asset, SENTI-202, to a Celadon-controlled private company. In return, public stockholders would receive contingent value rights (CVRs) that could pay up to $60 million if regulatory and sales milestones are met—yet the company's own analysis shows a liquidation would yield $0.00 per share. The deal includes a reverse stock split to maintain Nasdaq listing and a $2.5 million termination fee. The proxy reveals a deeply distressed company with a going-concern warning, no viable alternatives, and a controlling shareholder driving the transaction. Lincoln's fairness opinion values the CVRs at $0.07–$0.20 per share on a risk-adjusted basis, far below the maximum potential payout, underscoring the high risk of no payment.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $0.42 to $2.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.